- Home
- MYFW vs CHRS Comparison
MYFW vs CHRS Comparison
Compare MYFW & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYFW
- CHRS
- Stock Information
- Founded
- MYFW 2002
- CHRS 2010
- Country
- MYFW United States
- CHRS United States
- Employees
- MYFW N/A
- CHRS 235
- Industry
- MYFW Major Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MYFW Finance
- CHRS Health Care
- Exchange
- MYFW Nasdaq
- CHRS Nasdaq
- Market Cap
- MYFW 170.9M
- CHRS 134.4M
- IPO Year
- MYFW 2018
- CHRS 2014
- Fundamental
- Price
- MYFW $21.21
- CHRS $1.16
- Analyst Decision
- MYFW Buy
- CHRS Strong Buy
- Analyst Count
- MYFW 3
- CHRS 4
- Target Price
- MYFW $21.83
- CHRS $5.38
- AVG Volume (30 Days)
- MYFW 29.5K
- CHRS 2.4M
- Earning Date
- MYFW 01-23-2025
- CHRS 03-12-2025
- Dividend Yield
- MYFW N/A
- CHRS N/A
- EPS Growth
- MYFW N/A
- CHRS N/A
- EPS
- MYFW 0.26
- CHRS N/A
- Revenue
- MYFW $79,649,000.00
- CHRS $304,340,000.00
- Revenue This Year
- MYFW N/A
- CHRS $2.47
- Revenue Next Year
- MYFW $12.86
- CHRS N/A
- P/E Ratio
- MYFW $81.36
- CHRS N/A
- Revenue Growth
- MYFW N/A
- CHRS 44.19
- 52 Week Low
- MYFW $12.84
- CHRS $0.66
- 52 Week High
- MYFW $22.32
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- MYFW 63.56
- CHRS 38.01
- Support Level
- MYFW $19.50
- CHRS $1.03
- Resistance Level
- MYFW $21.19
- CHRS $1.39
- Average True Range (ATR)
- MYFW 0.83
- CHRS 0.14
- MACD
- MYFW 0.35
- CHRS -0.03
- Stochastic Oscillator
- MYFW 98.40
- CHRS 14.04
About MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.